BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18936477)

  • 1. Clinical outcome and predictors of survival in late relapse of germ cell tumor.
    Sharp DS; Carver BS; Eggener SE; Kondagunta GV; Motzer RJ; Bosl GJ; Sheinfeld J
    J Clin Oncol; 2008 Dec; 26(34):5524-9. PubMed ID: 18936477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
    Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
    BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
    Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
    Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reoperative retroperitoneal lymph node dissection for metastatic germ cell tumors: analysis of local recurrence and predictors of survival.
    Pedrosa JA; Masterson TA; Rice KR; Bihrle R; Beck SD; Foster RS
    J Urol; 2014 Jun; 191(6):1777-82. PubMed ID: 24518787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical management of late relapse on surveillance in patients presenting with clinical stage I testicular cancer.
    Rice KR; Beck SD; Pedrosa JA; Masterson TA; Einhorn LH; Foster RS
    Urology; 2014 Oct; 84(4):886-90. PubMed ID: 25260450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeat retroperitoneal lymph-node dissection after chemotherapy for metastatic testicular germ cell tumour.
    Willis SF; Winkler M; Savage P; Seckl MJ; Christmas TJ
    BJU Int; 2007 Oct; 100(4):809-12. PubMed ID: 17711512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the role of enlarged lymph node resection alone in patients with nonseminomatous germ cell tumor who had stage II or III disease?
    Ekenel M; Keskin S; Sanli Ö; Bavbek S; Tunç M; Ander H; Ozcan F; Kiliçaslan I; Başaran M
    Clin Genitourin Cancer; 2012 Sep; 10(3):185-9. PubMed ID: 22682983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contemporary management of postchemotherapy testis cancer.
    Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
    Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
    Dash A; Carver BS; Stasi J; Bajorin DF; Motzer RJ; Bosl GJ; Sheinfeld J
    Cancer; 2008 Feb; 112(4):800-5. PubMed ID: 18172902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
    Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
    J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
    Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
    BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center.
    Necchi A; Farè E; Vullo SL; Giannatempo P; Raggi D; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Verzoni E; Grassi P; Procopio G; Pizzocaro G; Mariani L; Salvioni R
    Clin Genitourin Cancer; 2015 Aug; 13(4):385-391.e1. PubMed ID: 25726505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes and histological findings of patients with advanced metastatic germ cell tumors undergoing post-chemotherapy resection of retroperitoneal lymph nodes and residual extraretroperitoneal masses.
    Nakamura T; Oishi M; Ueda T; Fujihara A; Nakanishi H; Kamoi K; Naya Y; Hongo F; Okihara K; Miki T
    Int J Urol; 2015 Jul; 22(7):663-8. PubMed ID: 25847721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymph Node Yield in Primary Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumors.
    Nayan M; Jewett MA; Sweet J; Anson-Cartwright L; Bedard PL; Moore M; Chung P; Warde P; Hamilton RJ
    J Urol; 2015 Aug; 194(2):386-91. PubMed ID: 25823792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors.
    Carver BS; Serio AM; Bajorin D; Motzer RJ; Stasi J; Bosl GJ; Vickers AJ; Sheinfeld J
    J Clin Oncol; 2007 Dec; 25(35):5603-8. PubMed ID: 17998544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression?
    Spiess PE; Tannir NM; Tu SM; Brown GA; Liu P; Kamat AM; Wood CG; Evans JG; Pisters LL
    Cancer; 2007 Dec; 110(12):2700-8. PubMed ID: 17948916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retroperitoneal lymph node dissection after chemotherapy in patients with elevated tumour markers: indications, histopathology and outcome.
    Ong TA; Winkler MH; Savage PM; Seckl MJ; Christmas TJ
    BJU Int; 2008 Jul; 102(2):198-202. PubMed ID: 18294302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. During twenty years of Cisplatin-based therapy the face of nonseminomatous testicular germ cell tumors is still changing: an evaluation of presentation, management, predictive factors and survival.
    Heinzelbecker J; Katzmarzik M; Weiss C; Trojan L; Haecker A
    Int Braz J Urol; 2013; 39(1):10-21. PubMed ID: 23489512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers.
    Habuchi T; Kamoto T; Hara I; Kawai K; Nakao M; Nonomura N; Kobayashi T; Ogawa O; Kamidono S; Akaza H; Okuyama A; Kato T; Miki T
    Cancer; 2003 Oct; 98(8):1635-42. PubMed ID: 14534879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of residual tumor resection in the management of nonseminomatous germ cell cancer of testicular origin.
    Schirren J; Trainer S; Eberlein M; Lorch A; Beyer J; Bölükbas S
    Thorac Cardiovasc Surg; 2012 Sep; 60(6):405-12. PubMed ID: 22383152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.